Peptibase
FDA ApprovedWeight Loss

Setmelanotide for Weight Loss

Research, mechanism, dosing, and effectiveness of Setmelanotide for weight loss.

Quick Answer

Setmelanotide is FDA-approved for rare genetic obesity disorders (POMC, LEPR deficiency).

Evidence Level

FDA Approved

Typical Dose

1-3 mg daily subcutaneous

Results Timeline

Weight loss in responsive patients over months

FDA Status

FDA Approved

How Setmelanotide Works for Weight Loss

MC4R agonist restores satiety signaling in specific genetic mutations.

About Weight Loss

Reduction of body fat and overall body weight through appetite control and metabolic enhancement.

Research Evidence

Approved for POMC, PCSK1, and LEPR deficiency obesity. Studies show significant weight loss in these specific populations where other treatments fail. Precision medicine approach. In March 2026, FDA approved an expanded indication for acquired hypothalamic obesity in adults and pediatric patients aged 4+. The Phase 3 TRANSCEND trial showed -18.4% placebo-adjusted BMI reduction.

Clinical Status:FDA Approved - Genetic obesities (BBS, POMC/PCSK1/LEPR deficiency) and acquired hypothalamic obesity (approved March 2026)

Dosing for Weight Loss

Recommended Dose

1-3 mg daily subcutaneous

Frequency

Once daily

Administration

Subcutaneous injection daily

Duration

Long-term / chronic use

Note: FDA-approved for specific genetic obesities (POMC, PCSK1, LEPR deficiency). Prescription only.

What to Expect

Week 1-2

Initial adjustment period. Some users may notice subtle changes.

Week 3-4

Early benefits often become noticeable. Continue consistent use.

Week 5-8

Most users report meaningful improvements by this point.

2-3 Months

Full effects typically realized. Reassess and adjust as needed.

Possible Side Effects

Not everyone experiences these. Individual responses vary.

  • •Skin hyperpigmentation (67-83%)
  • •Injection site reactions
  • •Nausea
  • •Spontaneous erections in males
  • •Priapism risk
  • •Depression risk

Frequently Asked Questions

Does Setmelanotide help with weight loss?

Setmelanotide is FDA-approved for rare genetic obesity disorders (POMC, LEPR deficiency).

How does Setmelanotide work for weight loss?

MC4R agonist restores satiety signaling in specific genetic mutations....

What dose of Setmelanotide should I use for weight loss?

1-3 mg daily subcutaneous

How long until I see results?

Weight loss in responsive patients over months

Other Peptides for Weight Loss

These peptides are also researched for weight loss.

Semaglutide

FDA

A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.

Tirzepatide

FDA

A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.

Orforglipron

FDA

An oral non-peptide GLP-1 receptor agonist. FDA approved April 1, 2026 under the brand name Foundayo — the first daily oral GLP-1 pill for weight loss. Distribution began April 6, 2026. FDA subsequently requested additional post-approval safety data.

Liraglutide

FDA

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.

View Full Setmelanotide ProfileHow to Use Setmelanotide